While large corporations like Google and Meta are curbing their DEI programs, Ulu Ventures, which just raised a fourth fund ...

Wedbush raised the firm’s price target on SpringWorks Therapeutics (SWTX) to $81 from $77 and keeps an Outperform rating on the shares ...

(Corrects third to last paragraph to say "the erosion from LOEs (loss of exclusivity)", not "from LOEs (levels of evidence)") ...

The German drugmaker confirmed acquisition talks, but cautioned a deal may not materialize. Elsewhere, Biohaven got priority ...

Germany’s Merck KGaA is in advanced talks to aquire the U.S. biopharmaceutical company that specializes in rare diseases and cancer.

Klaus joins Epitopea after serving as Chief Development Officer (CDO) at Nykode Therapeutics, where he oversaw clinical development, regulatory affairs, and project management across oncology, ...